Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 trial of apremilast in rheumatoid arthritis with inadequate response to methotrexate
2010-019926-15Phase 2Terminated
- Sponsor
- Celgene Corporation
- Start
- Dec 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of apremilast in rheumatoid arthritis (RA) (3 arms), sponsored by Celgene Corporation. Primary endpoint: ACR response at week 24. Started Dec 2010; status: terminated.
02
Drugs
apremilast
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2010-019926-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019926-15.